ADC Therapeutics (ADCT) to Release Earnings on Monday

ADC Therapeutics (NYSE:ADCT - Get Free Report) will be issuing its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.56). The business had revenue of $16.79 million for the quarter, compared to analysts' expectations of $16.58 million. ADC Therapeutics had a negative net margin of 344.15% and a negative return on equity of 1,313.37%. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Trading Up 0.4 %

Shares of ADCT traded up $0.02 on Thursday, reaching $4.73. 279,091 shares of the company's stock traded hands, compared to its average volume of 720,019. The stock has a market cap of $391.69 million, a PE ratio of -1.61 and a beta of 1.69. The stock's 50 day simple moving average is $4.59 and its two-hundred day simple moving average is $2.78. ADC Therapeutics has a 52-week low of $0.36 and a 52-week high of $6.04.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Royal Bank of Canada reissued an "outperform" rating and set a $8.00 price objective on shares of ADC Therapeutics in a report on Thursday, March 14th. Guggenheim reaffirmed a "buy" rating on shares of ADC Therapeutics in a report on Friday, April 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of ADC Therapeutics in a report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, ADC Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.